Veracyte, Inc.(VCYT)NASDAQ
Company Profile & Information
Company Profile
Business overview, scale, and footprint
Business Overview
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services.
The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Insider Transactions
Open-market activity and option exercises
Insider Activity Summary
Insider trading activity for Veracyte, Inc. (VCYT) over the last 3 months consists of 118 total transactions. Among these, company executives and board members conducted 118 buys (totaling 2,127,004 shares) and 0 sells (totaling 0 shares). This activity resulted in a net change of 2,127,004 shares, reflecting net buying interest with an estimated net acquisitions value of $201.97M.
118 insider transactions found. Showing 10 of 118 transactions.
| Insider Name | Relation to Company | Shares Changed | Price | Transaction Date |
|---|---|---|---|---|
| EASTHAM KARIN | Director | 3,729 | $0.20 | Jun 18, 2026 |
| SHAFER DAVID BRENT | Director | 5,272 | $N/A | Jun 11, 2026 |
| HOLSTEIN JENS | Director | 5,272 | $N/A | Jun 11, 2026 |
| BHANJI MUNA | Director | 5,272 | $N/A | Jun 11, 2026 |
| BARR ELIAV | Director | 5,272 | $N/A | Jun 11, 2026 |
| MILLER THOMAS F | Director | 5,272 | $N/A | Jun 11, 2026 |
| JONES EVAN | Director | 5,272 | $N/A | Jun 11, 2026 |
| EPSTEIN ROBERT S | Director | 5,272 | $N/A | Jun 11, 2026 |
| EASTHAM KARIN | Director | 5,272 | $N/A | Jun 11, 2026 |
| LEITE JOHN | Officer | 13,975 | $0.70 | Jun 4, 2026 |